Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.3.0.814
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenue:        
Contract research revenue $ 59,858 $ 0 $ 194,494 $ 0
Costs and Expenses:        
Research and development 879,196 1,069,716 3,682,336 3,261,747
General and administrative 1,339,430 1,535,617 3,641,337 3,893,100
Total costs and expenses 2,218,626 2,605,333 7,323,673 7,154,847
Loss from operations (2,158,768) (2,605,333) (7,129,179) (7,154,847)
Other income (expense), net 4,143 (6,495) (88) (21,876)
Net loss $ (2,154,625) $ (2,611,828) $ (7,129,267) $ (7,176,723)
Net loss per share - basic and diluted (in dollar per share) $ (0.04) $ (0.08) $ (0.14) $ (0.22)
Weighted average common shares outstanding:        
Basic and diluted (in shares) 56,970,295 32,060,796 49,574,729 32,020,265